Literature DB >> 18650111

[Should elderly patients with glioblastoma be proposed to radiotherapy?].

S Lopez1, S Taillibert, A Idbaih, J-M Simon, J-J Mazeron.   

Abstract

In glioblastoma multiform-patients, advanced age has been associated with poor prognosis and decreased tolerance to treatments. The optimal management, especially with irradiation, was not definitively determined in the eighth and ninth decades. The Association of French-speaking neuro-oncologists (Anocef) has recently conducted a randomized clinical trial comparing radiotherapy plus supportive care versus supportive care alone in such patients. Patients aged 70-years and older with newly diagnosed glioblastoma and a Karnofsky performance score of 70 or above were randomly assigned to receive focal irradiation in daily fraction of 1.8 Gy given five days per week for a total dose of 50 Gy plus supportive care or supportive care only. Radiotherapy resulted in a modest but significant improvement in overall survival without reducing quality of life or cognition. However, the optimal regimen of radiotherapy in this fragile population remains uncertain. Abbreviated course of radiotherapy (40 Gy in 15 fractions over 19 days) has been proposed. Analysis of preliminary results showed that efficacy and safety of this hypofractionated accelerated regimen compared favourably with those of classically fractionated treatments. Finally, the potential contribution of surgery and chemotherapy should be evaluated in prospective clinical trials.

Entities:  

Mesh:

Year:  2008        PMID: 18650111     DOI: 10.1016/j.canrad.2008.05.003

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  3 in total

1.  Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. Clinical article.

Authors:  Kaisorn L Chaichana; Aditya N Halthore; Scott L Parker; Alessandro Olivi; Jon D Weingart; Henry Brem; Alfredo Quinones-Hinojosa
Journal:  J Neurosurg       Date:  2010-06-04       Impact factor: 5.115

2.  Radiotherapy with or without temozolomide in elderly patients aged ≥ 70 years with glioblastoma.

Authors:  Evrim Metcalfe; Ozden Karaoglanoglu; Emine Akyazici
Journal:  Contemp Oncol (Pozn)       Date:  2016-08-04

3.  Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma.

Authors:  Matteo Santoni; Silvia Scoccianti; Ivan Lolli; Maria Grazia Fabrini; Giovanni Silvano; Beatrice Detti; Franco Perrone; Giuseppina Savio; Roberto Iacovelli; Luciano Burattini; Rossana Berardi; Stefano Cascinu
Journal:  J Neurooncol       Date:  2013-04-06       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.